CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F18%3AN0000016" target="_blank" >RIV/00023728:_____/18:N0000016 - isvavai.cz</a>

Result on the web

<a href="http://www.jrheum.org/content/45/1/22" target="_blank" >http://www.jrheum.org/content/45/1/22</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3899/jrheum.161238" target="_blank" >10.3899/jrheum.161238</a>

Result language

angličtina

Original language name

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study

Original language description

To evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CNTO6785, a fully human monoclonal antibody that binds to human interleukin 17A, in patients with active rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX) therapy.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JOURNAL OF RHEUMATOLOGY

ISSN

0315-162X

e-ISSN

1499-2752

Volume of the periodical

45

Issue of the periodical within the volume

1

Country of publishing house

CA - CANADA

Number of pages

10

Pages from-to

22-31

UT code for WoS article

000418943400005

EID of the result in the Scopus database

2-s2.0-85040077437